menu
    • menu
    [{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"PNT2001","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Eckert & Ziegler Strahlen \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Eckert & Ziegler Strahlen \/ POINT Biopharma"},{"orgOrder":0,"company":"Eckert & Ziegler Strahlen","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"TLX592","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Eckert & Ziegler Strahlen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eckert & Ziegler Strahlen \/ Telix Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Eckert & Ziegler Strahlen

    Menu

    Eckert & Ziegler Strahlen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TLX592

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

                            Details : The partnership aims to provide Telix with both an additional commercial source of 225Ac and access to a platform technology for use in the development of next generation TATs, including TLX592.

                            Brand Name : TLX592

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : TLX592

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Telix Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Eckert & Ziegler Strahlen

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT2001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Eckert & Ziegler to Supply POINT Biopharma with Actinium-225

                            Details : Under the agreement, Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands, including PSMA-targeted PNT2001 program.

                            Brand Name : PNT2001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 04, 2023

                            Lead Product(s) : PNT2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Point Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth